|Videos|September 11, 2020

Standard of Care in Patients With Heart Failure

Episodes in this series

EP. 1 Pathophysiology of Different Types of Heart Failure

EP. 2 Progressive Nature and Associated Risks of Diabetes on HF

EP. 3 Cost and Utilization Profile for a Patient With HF

EP. 4 Economic Burden of Heart Failure and Goals of Treatment

Now Playing

EP. 5 Standard of Care in Patients With Heart Failure

EP. 6 Reducing Readmissions Due to Heart Failure

EP. 7 CV Outcomes Studies With Medications Indicated for Diabetes

EP. 8 Recent Studies of SGLT-2s in Patients with HFrEF

EP. 9 Implications of Using SGLT2 Inhibitors With HFpEF and HFrEF

EP. 10 SGLT2 Inhibitors in Patients Without Diabetes at Risk of HF

EP. 11 SGLT2 Inhibitors as Standard of Care Throughout Cardiology

EP. 12 Guidelines Regarding Use of SGLT2s for Patients With Diabetes and HF

EP. 13 Quantifying Potential Impact of SGLT2 Inhibitors for HF

EP. 14 Systemic Change to Support Care of Patients With HF

EP. 15 Treatment of Patients With Heart Failure

EP. 16 Interest Regarding Diabetes and CVD Risk

EP. 17 Takeaways of DAPA-HF: SGLT2s for CVD

EP. 18 Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits

EP. 19 Cost-Effectiveness of SGLT2s for CVD

Cardiologists review the current pharmacologic treatment options and evaluate hospitalization rates across use of traditional heart failure medications.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Culturally Tailored Diabetes Care Can Improve Outcomes and Reduce Costs: Alyson K. Myers, MD

ByGiuliana Grossi,Alyson K. Myers, MD

June 6th 2026

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

ByGiuliana Grossi,Kevin Kaiserman, MD

June 6th 2026

Diabetes concept | Image credit: Sherry Young - stock.adobe.com

Surgery for Diabetic Gastroparesis May Improve HbA1c and Reduce Complications

ByPearl Steinzor

June 3rd 2026

What Managed Care Should Watch at ADA 2026 Scientific Sessions

ByMaggie L. Shaw

June 3rd 2026

Child with diabetes | Image credit: Africa Studio - stock.adobe.com

FDA Approves Inhaled Insulin for Children, Adolescents With Diabetes

ByPearl Steinzor,Giuliana Grossi

May 29th 2026

Standard of Care in Patients With Heart Failure

Episodes in this series

EP. 1 Pathophysiology of Different Types of Heart Failure

EP. 2 Progressive Nature and Associated Risks of Diabetes on HF

EP. 3 Cost and Utilization Profile for a Patient With HF

EP. 4 Economic Burden of Heart Failure and Goals of Treatment

EP. 5 Standard of Care in Patients With Heart Failure

EP. 6 Reducing Readmissions Due to Heart Failure

EP. 7 CV Outcomes Studies With Medications Indicated for Diabetes

EP. 8 Recent Studies of SGLT-2s in Patients with HFrEF

EP. 9 Implications of Using SGLT2 Inhibitors With HFpEF and HFrEF

EP. 10 SGLT2 Inhibitors in Patients Without Diabetes at Risk of HF

EP. 11 SGLT2 Inhibitors as Standard of Care Throughout Cardiology

EP. 12 Guidelines Regarding Use of SGLT2s for Patients With Diabetes and HF

EP. 13 Quantifying Potential Impact of SGLT2 Inhibitors for HF

EP. 14 Systemic Change to Support Care of Patients With HF

EP. 15 Treatment of Patients With Heart Failure

EP. 16 Interest Regarding Diabetes and CVD Risk

EP. 17 Takeaways of DAPA-HF: SGLT2s for CVD

EP. 18 Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits

EP. 19 Cost-Effectiveness of SGLT2s for CVD

Related Content

Culturally Tailored Diabetes Care Can Improve Outcomes and Reduce Costs: Alyson K. Myers, MD

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

Surgery for Diabetic Gastroparesis May Improve HbA1c and Reduce Complications

What Managed Care Should Watch at ADA 2026 Scientific Sessions

FDA Approves Inhaled Insulin for Children, Adolescents With Diabetes

Trending on AJMC

Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

Delgocitinib Coverage Could Save Health Plans $88M Over 3 Years

COVID Postexposure Prophylaxis Expands Prevention Toolkit: Noah Greenspan, DPT, PT